Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On September 29, 2025, Soligenix, Inc. (SNGX) announced the closing of a previously announced public offering that resulted in gross proceeds of approximately $7.5 million through the sale of 5,555,560 shares of common stock at a price of $1.35 and warrants to purchase up to 5,555,560 shares of common stock at an exercise price of $1.35 per share.</li><li>Following this financing, we estimate that the company has sufficient capital to fund operations through the end of 2026, which is beyond several anticipated key inflection points.</li><li> On September 30, 2025, Soligenix announced the expansion of its European Medical Advisory Board to provide additional strategic guidance as the company advances its Phase 3 trial of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL).</li></ul>

On September 29, 2025, Soligenix, Inc. (SNGX) announced the closing of a previously announced public offering that resulted in gross proceeds of approximately $7.5 million through the sale of 5,555,560 shares of common stock at a price of $1.35 and warrants to purchase up to 5,555,560 shares of common stock at an exercise price of $1.35 per share.Following this financing, we estimate that the company has sufficient capital to fund operations through the end of 2026, which is beyond several anticipated key inflection points. On September 30, 2025, Soligenix announced the expansion of its European Medical Advisory Board to provide additional strategic guidance as the company advances its Phase 3 trial of HyBryte in the treatment of cutaneous T cell lymphoma (CTCL).

SNGX: Public Offering Raises 7.5 Million  Expands European Medical Advisory Board